Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Non-Deal Roadshow (June 2022)
47 slides from Piramal Pharma's roadshow presentation, June 2022
Slide 1: Roadshow Presentation
Roadshow Presentation June 2022 0
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and any subsequent discussions, which include words or phrases such as 'will', 'aim', 'will likely result', 'would', 'believe', 'may', 'expect', 'will continue', 'anticipate', 'estimate', 'intend', 'pl
Slide 3: Three-Pronged Business Model with Market Leading Positions
Three-Pronged Business Model with Market Leading Positions... Complex Hospital Generics India Consumer Healthcare CDMO (CHG) (ICH) 13 CDMO sites across North America, Europe and India Inhalation Anesthesia Anesthesia and pain management Ahmedabad1 Pithampur Grangemouth Aurora Turbhe Morpeth Mahad In
Slide 4: In Attractive and Large Industry Segments
…in Attractive and Large Industry Segments Complex Hospital Generics India Consumer Healthcare CDMO (CHG) (ICH) CDMO Market Growing at a …With Robust Growth in Small Healthy Pace… Molecule CDMOs Addressable market size of CHG Addressable market size of ICH (In USD Bn) (In USD Bn)1 CAGR of 7% CAGR of
Slide 5: Levers for Sustainable Value Creation
Levers for Sustainable Value Creation 1 Global Footprint with a Diversified Revenue Base 2 Balanced Manufacturing Footprint with Best-in-Class Quality Track Record 3 Track Record of Inorganic and Organic Expansion 4 Strong Financial Performance Across Segments over a Sustained Period of Time 5 Insti
Slide 6: Global Footprint with a Diversified Revenue Base
1 Global Footprint with a Diversified Revenue Base 15 100+ ~500 6,000+ Manufacturing Sites Countries Countrieswith with CDMO Customers CHG Customers Commercial commercialPresence presence (Hospitals) Total FY22 Revenue by Geography Total FY22 Revenue by Segments India Consumer Other Healthcare 10% N
Slide 7: Balanced Manufacturing Footprint
Balanced Manufacturing Footprint with Capability to meet a Wide-range 2 of Customer Geographic Requirements… 15 Manufacturing & Development facilities across North America, United Kingdom and India 5 2 8 North America United Kingdom India1 API, Highly Potent API (HPAPI), API, ADC (Antibody Drug Conj
Slide 8: Best-in-Class Quality Track Record
2 …with Best-in-Class Quality Track Record 280 36 Zero ~150 total regulatory USFDA inspections OAIs1,2 annual customer audits 1 inspections1 successfully cleared1 ✓ Strong quality function with 1,000 people across sites and reporting directly to the Chairperson Advancement journey from 'Quality for
Slide 9: Track Record of Organic and Inorganic Expansion
3 Track Record of Organic and Inorganic Expansion ✓ Growth capex across Discovery, Development and Commercial Manufacturing within CDMO Healthy ROI on Organic Investments ✓ Investments to bolster capacity across key Inhalation Anesthesia products in Complex Hospital Generics ✓ Sales Promotion to dri
Slide 10: Strong Financial Performance Across Segments over a Sustained Period of Time
Strong Financial Performance Across Segments over a Sustained 4 Period of Time Strong Growth Across Segments with Increasing Profitability Strong Growth in FY22 in a Challenging Macro Environment (Revenue In INR Crore) (Revenue In INR Crore) FY12-22 CAGR FY21-22 yoy 6,701 6,701 16% 13% 741 5,776 741
Slide 11: Institutional Focus on ESG
5 Institutional Focus on ESG Established ESG Framework… …with Significant Impact Environment Energy Business Ethics and Management Compliance ~83K 574K Trees planted during Tons of CO2e offset FY22 during FY22 Water Stewardship and Responsible Waste Management Supply Chain ~123K ~147K KLs of treated
Slide 12: Focus on Patient and Customer Centricity
6 Focus on Patient and Customer Centricity: source of differentiation Focusing on Patient-centricity and Customer-centricity drives our organization to provide flexible high-quality service while aligning us ✓ with our customer partners on our shared goal of serving patients CDMO Complex Hospital Ge
Slide 13: Highly Experienced Management Team Across Business Segments
7 Highly Experienced Management Team Across Business Segments… Strategic Group Leadership Nandini Piramal Peter DeYoung Chairperson, CEO, Global Pharma Piramal Pharma Business Leadership team Herve Berdou Stuart Needleman Michael Logerfo Nitish Bajaj COO – CDMO CCO – CDMO President & COO – CEO – Ind
Slide 14: Demonstrating Execution Against Key Strategic Priorities
7 …Demonstrating Execution Against Key Strategic Priorities Strategic Priorities PPL’s Execution ▪ $157m of Growth-oriented capex committed across multiple sites for the CDMO business Continued Organic ✓ ▪ 129cr. (19% of revenue) spent on Media and Trade spends (1.8x FY20 spend), resulting in ~48% y
Slide 15: CDMO
6 Piramal Pharma Limited CDMO
Slide 16: CDMO Business at a Glance
CDMO Business at a Glance 1 Service Offerings Across the Lifecycle of the Molecule 2 High Proportion of Commercial Revenues and a Deep Pipeline of Development Projects across Multiple Phases 3 Diversified Blue Chip Customer Base 4 Increasing Revenue Share and Attracting Customers with our Differenti
Slide 17: Service Offerings Across the Lifecycle of the Molecule
1 Service Offerings Across the Lifecycle of the Molecule… CDMO CHG ICH Discovery Development Commercial Manufacturing >90% 172 50+ 65+ Pipeline of molecules across FDFs across therapeutic areas and business from repeat clients APIs across therapeutic areas phases 1, 2 and 3 dosage forms 95% 46% Abil
Slide 18: High Proportion of Commercial Revenues and a Deep Development Pipeline
…with a High Proportion of Commercial Revenues and a Deep Pipeline 2 of Development Projects across Multiple Phases CDMO CHG ICH Strengthened Molecule Pipeline across Clinical Phases with 3.4x Growth High Proportion of Commercial and Phase 3 Development Revenue in Phase-III Molecules since FY17 FY22
Slide 19: Diversified Blue Chip Customer Base
3 Diversified Blue Chip Customer Base CDMO CHG ICH We have an Attractive Customer Mix… … with Low Revenue Concentration % of Revenue FY22 Revenue #1 #2 5% 5% Generics Big Pharma 29% 32% 71% of revenue from #3 Big Pharma, 5% Others #4 FY22 Emerging Biopharma, 61% FY22 Over 500 5% customers Customer 7
Slide 20: Increasing Revenue Share from Differentiated Offerings
Increasing Revenue Share and Attracting Customers with our 4 Differentiated Offerings CDMO CHG ICH While we serve most therapeutic areas, our focus has helped Increasing revenue contribution from differentiated offerings build presence in high growth areas such as oncology % of revenue 22% 65 Potent
Slide 21: Adding capabilities through successful acquisitions
4 Adding capabilities through successful acquisitions CDMO CHG ICH Acquired 100% stake in Hemmo Pharmaceuticals, enabling expansion into Peptide API ✓ One of the few pure-play Peptide API players globally ✓ Upfront consideration of INR 775 Crores and earn-outs linked to achievement of milestones ✓ A
Slide 22: Global Manufacturing Footprint with Customer-led Brownfield Expansions
Global Manufacturing Footprint with Expansion of Major Sites through 5 Customer-led Brownfield Expansions CDMO CHG ICH Balanced Manufacturing Footprint with Capability to meet a Wide-range of Customer Geographic Requirements North America United Kingdom India 4 2 7 13 Global Ahmedabad1 Pithampur Fac
Slide 23: Leveraging our End-to-end Model to offer Integrated Services
6 Leveraging our End-to-end Model to offer Integrated Services CDMO CHG ICH Implementation of Integrated Services in Oncology Clear Benefits of the Integrated1 Platform Facility Offering Ahmedabad Discovery Services 170+ 1.5x Increase in number of Integrated projects integrated projects from Rivervi
Slide 24: Track Record of Consistent Above-Market Growth
7 Track Record of Consistent Above-Market Growth CDMO CHG ICH Revenue Growth FY22 Revenue Performance Revenue Contribution to PPL (In INR Crore) (In INR Crore) 11% CAGR +10% 3,960 3,960 3,616 FY22 revenue: INR 3,960 Crs 2,454 59% 1,355 Regional Share of Revenue FY22 CDMO Revenue FY12 FY17 FY22 FY21
Slide 25: Clearly Identified Levers of Growth
8 Clearly Identified Levers of Growth CDMO CHG Consumer ICH HC Strong visibility on commercial Capacity expansion through revenues with deep pipeline of continued investments and development projects operational excellence across clinical phases Increase revenue share and Adding capabilities through
Slide 26: Complex Hospital Generics
6 Piramal Pharma Limited Complex Hospital Generics
Slide 27: CHG Business at a Glance
CHG Business at a Glance 1 Differentiated Portfolio for Gaining Market Share and Driving Growth 2 Strong Pipeline in Niche Areas with Unique Characteristics 3 Vertically Integrated Manufacturing Capabilities and Well Built Out Commercial Infrastructure CHG 4 Track Record of High Growth 5 Clearly Ide
Slide 28: Leveraging our Differentiated Portfolio for Gaining Market Share
Leveraging our Differentiated Portfolio for Gaining Market Share and 1 Driving Growth CDMO CHG ICH Differentiated portfolio of 40 products spanning inhalation anesthesia and injectable Inhalation Anesthesia Injectable Anesthesia (67% 1) and pain management (19% 1) #1 #4 in Intrathecal in Inhalation
Slide 29: Strong Pipeline in Niche Areas with Unique Characteristics
2 Strong Pipeline in Niche Areas with Unique Characteristics CDMO CHG ICH Building pipeline in niche areas… …by leveraging internal capabilities and key partnerships Injectable Anesthesia Pain Management ✓ Development and manufacturing partners around the globe A broad range of other Our internal re
Slide 30: Vertically Integrated Manufacturing and Commercial Infrastructure
Vertically Integrated Manufacturing Capabilities and Well Built Out 3 Commercial Infrastructure CDMO CHG ICH Key Starting Material Finished Products Distribution Direct Sales Vertically Integrated Manufacturing Capabilities1 with Global Regulatory Accreditations Commercial Presence through a Combina
Slide 31: Track Record of High Growth
4 Track Record of High Growth CDMO CHG ICH Revenue Growth FY22 Revenue Performance Revenue Contribution to PPL (In INR Crore) (In INR Crore) 17% CAGR +20% CHG FY22 2,002 revenue: 2,002 30% INR 2,002 Crs 1,669 1,064 413 Revenue by Geography FY22 CHG Revenue FY12 FY17 FY22 FY21 FY22 US Europe Japan Ot
Slide 32: Clearly Identified Levers of Growth
5 Clearly Identified Levers of Growth CDMO CHG ICH Developing and commercializing a Leveraging our differentiated strong pipeline of products in niche portfolio for gaining market share areas with unique characteristics and driving growth Continuing vertical integration Carrying out synergistic prod
Slide 33: India Consumer Healthcare
6 Piramal Pharma Limited India Consumer Healthcare
Slide 34: ICH Business at a Glance
ICH Business at a Glance 1 Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing 2 Launching Multiple New Products and Brand Extensions 3 Well Established Commercial Infrastructure with Multi-channel Distribution Strategy ICH 4 Track Record of High Growth 5 Clearly Ident
Slide 35: Focus on Power Brands with Continuous Investments in Brand Promotion
Focus on Power Brands with Continuous Investments in Brand 1 Promotion and Marketing CDMO CHG ICH Investments in Brand Promotion and Marketing… Kareena Kapoor Priyanka Mohan Sourav Ganguly Amyra Dastur Ajay Devgan Subodh Bhave Little’s Lacto - South India Polycrol Lacto - HSM belt Tetmosol Naturolax
Slide 36: Launching Multiple New Products and Brand Extensions
2 Launching Multiple New Products and Brand Extensions CDMO CHG ICH #4 #1 #2 #2 #3 40 New Products during FY22 Diaper Activity Ball Peel-Off Hygiene Wash Menstrual Cup 18 New SKUs during FY22 #2 #2 #4 #5 #1 15% Share of revenue from new products launched since Apr’20 Liquid Detergent Stacking Cube G
Slide 37: Well Established Commercial Infrastructure with Multi-channel Distribution
Well Established Commercial Infrastructure with Multi-channel 3 Distribution Strategy CDMO CHG ICH Well-entrenched in Traditional Channels Strengthening Presence in Alternate Channels Revenue share of 10% 22% alternate channels1 (FY20) (FY22) ✓ Presence in ~200K chemists and cosmetics stores and 10K
Slide 38: Track Record of High Growth
4 Track Record of High Growth CDMO CHG ICH Revenue Growth FY22 Revenue Performance Revenue Contribution to PPL (In INR Crore) (In INR Crore) +48% 11% 18% CAGR 741 741 ICH 501 FY22 revenue: INR 741 Crs 375 138 Revenue by Category in ICH FY12 FY17 FY22 FY21 FY22 Covid Others Protect 1% Women's Health
Slide 39: Clearly Identified Levers of Growth
5 Clearly Identified Levers of Growth CDMO CHG ICH Focusing on Power Brands through focused efforts on Launching multiple New Products and brand promotion and Brand Extensions marketing Strengthening presence at Strengthen Sales through alternate channels of Tech enablement distribution 38
Slide 40: Ophthalmology Branded Products
Ophthalmology Branded Products
Slide 41: Strategic Ophthalmology JV with a #1 Position in the Domestic Market
Strategic Ophthalmology JV with a #1 Position in the Domestic Market JV Arrangement Ownership Ownership #1 425 49% 51% in Indian employees including Ophthalmology Market sales force Revenue1 (INR Cr.) 9% CAGR Strong 414 presence 30% 329 in major disease FY22 PAT Margin segments 169 FY12 FY17 FY22 No
Slide 42: To Summarise
6 Piramal Pharma Limited To Summarise
Slide 43: To Summarise: Three Pillars of the Business
To Summarise Solid ThreeThree Pillars Pillars of theof Top 3 Top 4 Top 10 the Business Business 1 CDMO in India in Inhalation in OTC in India (Top 13th Globally) Anesthesia Globally Diversified Manufacturing Footprint Footprint withwith Strong 15 36 Nil Best-in-class Quality Track Record Manufacturi
Slide 44: Additional Supporting Slides
Additional Supporting Slides
Slide 45: Key Strategic Priorities
Key Strategic Priorities 1 Delivering consistent revenue growth and improving profitability 2 Pursuing organic and inorganic growth opportunities leveraging fresh capital Track record of building scalable differentiated ✓ Capacity expansion across multiple sites pharma businesses with ✓ Acquisitions
Slide 46: CDMO Market – Large and Growing Addressable Market
CDMO Market – Large and Growing Addressable Market CDMO CHG ICH CDMO Market Growing at a Healthy Pace… …Driven by Sustainable Tailwinds (In USD Bn) CAGR of 7% 169 ✓ New Businesses will emerge within Biotech and Mid Pharma 115 ✓ US and Asia Pacific witnessing higher growth of 7.7–8.5% p.a. over 2021–
Slide 47: Broad Portfolio Spanning Inhalation Anesthesia, Pain Management and Specialty Products
Broad Portfolio Spanning Inhalation Anesthesia, Pain Management, Intrathecal Therapy, Generic Injectables and Specialty Products CDMO CHG ICH Pre-2016 2016-2022 Injectables Inhalation Anesthesia Product Category Anesthesia Intrathecal Therapy Other Injectables and pain management Level of Low Medium